Abstract
Background Natural killer (NK) cells originate from bone marrow precursors and mediate effective anti-tumor responses. Clinical trials of cytokine-primed memory-like (ML) NK cells in acute myeloid leukemia (AML) have demonstrated activity without major toxicity, including graft-versus-host disease or cytokine release syndrome. However, broad application of non-expanded, non-engineered ML NK cells has been hindered by limited availability of NK cells from a single donor, thereby precluding aggressive dose escalation and repeat dosing. W-NK1 is derived from human peripheral blood mononuclear cells undergoing ML reprogramming with a proprietary heteromeric fusion protein complex including IL-12, IL-15 and IL-18.
Methods We conducted a multi-omics characterization of W-NK1 by interrogating its transcriptomic, proteomic and metabolic profile. Using functional assays, we assessed W-NK1’s cytotoxicity under adverse culture conditions, as well as W-NK1’s trafficking and killing abilities in immunodeficient mice engrafted with THP-1 AML. Finally, we evaluated W-NK1’s phenotype and in vivo expansion kinetics in one patient with AML enrolled in study NCT05470140.
Results W-NK1 displayed an activated, hyper-metabolic, and proliferative state differing from unstimulated conventional NK cells (cNK) from healthy donors. When compared to external single-cell NK datasets, W-NK1 was largely annotated as NKG2A+ and showed low relatedness with adaptive NK states characterized by HCMV-induced inflammatory memory. W-NK1 outperformed cNK cells in terms of in vitro killing of a broad panel of AML cell lines, with no appreciable cytotoxicity against normal cell lines. The expression of nutrient transporters was higher in W-NK1 compared to cNK cells and was retained even in adverse culture conditions designed to mimic an immunosuppressive tumor microenvironment. In mice engrafted with THP-1 AML, W-NK1 trafficked and efficiently homed to the bone marrow, where it mediated better tumor control than cNK cells. W-NK1 expanded, underwent phenotypic changes and persisted with effective elimination of circulating AML blasts through day 14 after infusion in one patient treated on clinical trial NCT05470140. Immunofluorescence staining of BM sections collected on day 28 showed increased expression of both CD56 and CD3 compared to a pre-treatment biopsy.
Conclusions Our study offers a comprehensive characterization of W-NK1 as an effective cell therapy product for AML and solid tumor malignancies.
What is already known on this topic Natural killer (NK) cells have been shown to be safe and effective for treating certain human malignancies. Nonetheless, limitations for adoptive cell therapy exist which include trafficking / homing to tumor tissues as well as metabolic resilience in an adverse microenvironment.
What this study adds W-NK1 is distinct transcriptionally and functionally from conventional NK cells with improved anti-tumor effector functions and metabolic adaptation in hostile culture conditions. Moreover, W-NK1 was readily detectable post-infusion in a patient with refractory acute myeloid leukemia.
How this study might affect research, practice or policy Our in vitro and in vivo findings indicate that W-NK1 is an effective NK-cell therapy product and augur positively for patients being treated in phase I immunotherapy clinical trials.
Competing Interest Statement
JV and SR received research support from Wugen, USA. MMB-E and TAF are inventors on patent/patent applications (15/983,275, 62/963,971, and PCT/US2019/060005) licensed to Wugen Inc. and held/submitted by Washington University that cover aspects of ML NK cell biology. This results in potential royalties to MMB-E, TAF, and Washington University from Wugen Inc. MMB-E has equity and consulting interest in Wugen Inc. TAF has research funding from HCW Biologics Inc., Wugen, Affimed, and the NIH during the conduct of the study, and equity, research funding, and consulting interest in Wugen Inc. Unrelated to this work, TAF also reports consulting for Affimed, Smart Immune, AI Proteins; and advises (equity interest) Indapta and OrcaBio. LA, NM, TL, AH, KM, JD, ES, BC, LL, JM, and JKDM are Wugen employees. The remaining authors declare no competing interests.
Clinical Trial
NCT05470140
Funding Statement
JV and SR are supported by the John and Lucille van Geest Foundation and by Nottingham Trent Universitys School of Science and Technology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has received approval from the Institutional Review Board of WCG (Western Copernicus Group), Princeton, NJ (Study Number: 1352242; IRB tracking number: 20226001). Participants gave informed consent to sample collection, which was performed as part of their routine clinical care.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
